TP53 mutations in human cancers: origins, consequences, and clinical use.

Keywords

Biology, Germline, Germline mutation, Genetics, Gene

References

• Screening for TP53 rearrangements in families with the Li–Fraumeni syndrome reveals a complete deletion of the TP53 geneAmy Higgins, Sherri Koucky — 2003
• Transcriptional control of human p53-regulated genesAntonio Cózar — 2008
• A review of contusugene ladenovec (Advexin) p53 therapy.Neil Senzer, John Nemunaitis — 2009
• Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: a comparison of the "hot spot" mutant phenotypes.Philip W. Hinds, Cathy A. Finlay, Robin S. Quartin — 1990
• Functional studies of a germ-line polymorphism at codon 47 within the p53 gene.Emanuela Felley‐Bosco, A Weston, Helen Cawley — 1993
• p53 and human cancer: the first ten thousand mutations.Pierre Hainaut, Monica Hollstein — 2000
• Role of a p53 polymorphism in the development of human papilloma-virus-associated cancerAlan Storey, Miranda Thomas, Ann Kalita — 1998
• Germline mutations in the TP53 gene.Rosalind A. Eeles — 1995
• Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype.Magali Olivier, David E. Goldgar, Nayanta Sodha — 2003
• TP53 mutation spectra and load: a tool for generating hypotheses on the etiology of cancer.Magali Olivier, S. Perwez Hussain, Claude Caron de Fromentel — 2004
• TP53 mutations in human skin cancersGiuseppina Giglia‐Mari, Alain Sarasin — 2003
• TP53 Status and Response to Chemotherapy in Breast CancerPhilippe Bertheau, Marc Espié, Elisabeth Turpin — 2008
• The role of TP53 in Cervical carcinogenesisMassimo Tommasino, Rosita Accardi, Sandra Caldeira — 2003
• Effect of the codon 72 polymorphism (c.215G>C, p.Arg72Pro) in combination with somatic sequence variants in the TP53 gene on survival in patients with advanced ovarian carcinomaYun Wang, Pedro Kringen, Gunnar B. Kristensen — 2004
• p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis.Daniele Bergamaschi, Milena Gasco, Louise Hiller — 2003
• Single-nucleotide polymorphisms in the p53 pathway regulate fertility in humansHey‐Joo Kang, Zhaohui Feng, Yvonne Sun — 2009
• TP53 mutation signature supports involvement of aristolochic acid in the aetiology of endemic nephropathy‐associated tumoursTatiana Nedelko, Volker M. Arlt, David H. Phillips — 2009
• Preferential Formation of Benzo[a]pyrene Adducts at Lung Cancer Mutational Hotspots in P53Mikhail F. Denissenko, Annie Pao, Moon‐shong Tang — 1996
• TP53 polymorphisms and lung cancer risk: a systematic review and meta-analysis.Athena Matakidou — 2003
• Widely dispersed p53 mutation in respiratory epithelium. A novel mechanism for field carcinogenesis.Wilbur A. Franklin, Adi F. Gazdar, John C. Haney — 1997

Cited by

• Role of TP53 Mutations in Vulvar CarcinomasMatthias Choschzick, Widianto Hantaredja, Pierre Tennstedt — 2011
• Genomic instability at the 13q31 locus and somatic mtDNA mutation in the D-loop site correlate with tumor aggressiveness in sporadic Brazilian breast cancer casesMaría Jesús Magdaleno — 2012
• The transcription factor FOXM1 (Forkhead box M1): proliferation-specific expression, transcription factor function, target genes, mouse models, and normal biological roles.Ying‐Nan Chiu — 2013
• Methyl Jasmonate: Putative Mechanisms of Action on Cancer Cells Cycle, Metabolism, and Apoptosis张治安 — 2014
• The genetic and epigenetic alterations in human hepatocellular carcinoma: a recent updateR Niesten — 2014
• Genetic prevention of lymphoma in p53 knockout mice allows the early development of p53-related sarcomasM. A. García Viñolas — 2014
• Tetramer formation of tumor suppressor protein p53: Structure, function, and applicationsThomas F. Necheles — 2016
• Somatic TP53 Mutations in the Era of Genome Sequencing.Francesca Dall'acqua — 2016
• Cell-Free DNA and Apoptosis: How Dead Cells Inform About the Living.Ron Davidson — 2020
• Biological evaluation of chlorogold complexes as potential anti-tumoural compounds: unraveling mechanisms of actionPedro Freire de Sousa Martins — 2014
• Treatment Strategies in Acute Myelogenous Leukemia : Investigating HSP90 and P53 as TargetsJennifer M. Napper — 2010
• p53 Expression as a marker of microinvasion in oral squamous cell carcinoma.Khor Goot Heah, Mohamed Ibrahim Abu Hassan, Siar Chong Huat — 2011
• Driving Brain Tumorigenesis: Generation and Biological Characterization of a Mutant IDH1 Mouse ModelChristopher J. Pirozzi — 2014
• Estudo de alterações genéticas associadas à leucemia/linfoma de células T do adulto no estado da BahiaMarcelo Magalhães Silva — 2012
• Inflammatory angiogenesis and the tumor microenvironment as targets for cancer therapy and prevention.Antonino Bruno, Arianna Pagani, Elena Magnani — 2014
• TP53 aberrations in chronic lymphocytic leukemia.Martin Trbušek, Jitka Malčíková — 2013
• Genetically Engineered Mice as Experimental Tools to Dissect the Critical Events in Breast CancerMitchell E. Menezes, Swadesh K. Das, Luni Emdad — 2014
• New methods for biological sequence alignment. (De nouvelles méthodes pour l'alignement des séquences biologiques)Marta Gîrdea, KUCHEROV, Gregory, NOE, Laurent — 2010
• Oncomorphic Tp53 mutations in advanced serous ovarian carcinomasPavla Brachova — 2014
• Quantitative analysis of p53 expression in human normal and cancer tissue microarray with global normalization method.Halliday Idikio — 2011

Related papers

• Analysis of global gene expression in adrenocortical tumors from Li-Fraumeni syndrome TP53 germline mutation carriers.Fábio Da Silva de Azevedo Fortes, Hellen Kuasne, Fábio Albuquerque Marchi — 2014
• The profile and contribution of rare germline copy number variants to cancer risk in Li-Fraumeni patients negative for TP53 mutationsAmanda G Silva, Ana Cristina Victorino Krepischi, P. Pearson — 2014
• Prevalence and penetrance of Li-Fraumeni cancer predisposition syndromeChang S. Chan — 2017
• Li‐Fraumeni versus Pseudo‐Li‐Fraumeni Syndrome: Key Insights for Interpreting Next‐Generation Sequencing Reports in Patients with Suspected Cancer Predisposition SyndromesSteven Sorscher, Rodwige J. Desnoyers, Karen Ouyang — 2017
• Two TP53 germline mutations in a classical Li-Fraumeni syndrome familyLiselotte P. van Hest, Mariëlle Ruijs, Anja Wagner — 2007
• Germline TP53 mutations and Li‐Fraumeni syndromeJM Varley — 2003
• Germline TP53 alterations in Finnish breast cancer families are rare and occur at conserved mutation-prone sitesKatrin Rapakko, Minna Allinen, Kirsi Syrjäkoski — 2001